6.A show cause memo dated 02.04.2009 under Section 18(a)(i) of the Act was served to M/s.Dadha Ganesh Pharmaceuticals, Pattabiram asking the details of purchase and distribution. By reply dated 02.04.2009, it had informed that the said drug was acquired from M/s. Dhandeep Pharma and Surgicals and a show cause memo was issued on 03.04.2009 to M/s.Dhandeep Pharma and Surgicals asking for details. M/s. Dhandeep Pharma replied that the said drug was acquired from M/s.Lehar Pharma Distributors. Thereafter, show cause Memo dated 17.04.2009 was issued to Lehar Pharma Distributors to furnish the details, they replied on 20.04.2009 that the said drug was acquired from Marksans Pharma Ltd., (formerly Glenmark Labs Ltd.,). Thereafter, show cause memo was issued on 22.04.2009 to M/s.Marksans Pharma Ltd., the said letter was returned to the complainant by postal authorities with endorsement “Left without address” on 11.05.2009. Thereafter, the respondent made a request to the Director of Drugs control for manufacture level investigation and in the carton of Rabi-20 it was manufactured by M/s.Zeus Pharmaceuticals, A1 and a Show cause notice dated 11.05.2009 with a copy of the analysis report as per section 25(2) of the Act was sent to A1 for the drug which has been declared as “not of standard quality”, which is punishable under Section 27-D of the Act. The third portion of the sample was sent to A1. A reply was from A1 dated 21.05.2009 was received by the complainant on 27.05.2009 that the sample as per their result was “OK”, but A1 have not submitted the drug license, endorsement of the said product in the drug license, details of the partnership of the firm, name of the authorized signatory.